<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181101</url>
  </required_header>
  <id_info>
    <org_study_id>SUCCESS-A</org_study_id>
    <secondary_id>2005-000490-21</secondary_id>
    <nct_id>NCT02181101</nct_id>
  </id_info>
  <brief_title>Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chugai Pharma USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Diagnostics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III&#xD;
      study comparing the disease free survival after randomisation in patients treated with 3&#xD;
      cycles of Epirubicin-Fluorouracil-Cyclophosphamide(FEC)-chemotherapy, followed by 3 cycles of&#xD;
      Docetaxel(Doc)-chemotherapy versus 3 cycles of Epirubicin-Fluorouracil-Cyclophosphamide(FEC),&#xD;
      followed by 3 cycles of Gemcitabine-Docetaxel(DocGemzar)-chemotherapy, and to compare the&#xD;
      disease free survival after randomisation in patients treated with 2 years of Zoledronate&#xD;
      versus 5 years of Zoledronate in patients with early primary breast cancer. Patients will be&#xD;
      required to have histopathological proof of axillary lymph node metastases (pN1-3) or high&#xD;
      risk node negative, defined as: 'pT≥2 or histopathological grade 3, or age ≤ 35 or negative&#xD;
      hormone receptor', but are not allowed to have evidence of distant disease. Patients will&#xD;
      have to be entered into the study no later than 6 weeks after complete resection of the&#xD;
      primary tumor. No other antineoplastic treatment other than surgical treatment, the defined&#xD;
      cytotoxic and endocrine treatment and radiotherapy will be allowed prior to study entry and&#xD;
      during the course of the study.&#xD;
&#xD;
      After surgery, leading to R0 resection of the invasive and intraductal components of the&#xD;
      primary tumor, patients will be randomized to one of the following treatments:&#xD;
&#xD;
      First randomization&#xD;
&#xD;
      AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v.&#xD;
      and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day&#xD;
      22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (Doc), and&#xD;
      Gemcitabine 1000 mg/m² i.v. (30 min infusion) (Gemzar), administered on day 1, followed by&#xD;
      Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22&#xD;
&#xD;
      AB: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v.&#xD;
      and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day&#xD;
      22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (Doc),&#xD;
      administered on day 1, repeated on day 22&#xD;
&#xD;
      Second randomization B&#xD;
&#xD;
      BA: Zoledronic acid 4 mg i.v., every 3 months for the duration of two years, subsequently&#xD;
      followed by zoledronic acid 4 mg i.v., every 6 months for the duration of additional three&#xD;
      years&#xD;
&#xD;
      BB: Zoledronic acid 4 mg i.v., every 3 months for the duration of two years&#xD;
&#xD;
      During the zoledronic acid treatment period, patients will receive 500 mg Calcium p.o. qid&#xD;
      and 400 i.E. Vitamin D p.o. qid.&#xD;
&#xD;
      Patients with positive hormone receptor status (≥ 10 % positively stained cells for estrogen&#xD;
      and/or progesterone) of the primary tumor will receive Tamoxifen treatment 20 mg p.o. per day&#xD;
      for 2 years, after the end of chemotherapy. Subsequent to chemotherapy, postmenopausal&#xD;
      patients with positive hormone receptor status will be treated with Anastrozole (Arimidex®) 1&#xD;
      mg p.o. for additional 3 years, premenopausal patients will continue Tamoxifen treatment for&#xD;
      additional 3 years. In addition to tamoxifen, all patients with positive hormone receptor&#xD;
      status of the primary tumor and under the age of 40 or restart of menstrual bleeding within 6&#xD;
      months after the completion of cytostatic treatment or with premenopausal hormone levels as&#xD;
      defined below will receive Goserelin (Zoladex®) 3.6 mg subcutaneously every 4 weeks over a&#xD;
      period of 2 years following chemotherapy. Premenopausal endocrine status will be assumed, if&#xD;
      the following serum levels are met: Luteinizing hormone (LH) &lt; 20 mIE/ml, follicle&#xD;
      stimulating hormone (FSH) &lt; 20 mIE/ml and estradiol (E2) &gt; 20 pg/ml. Endocrine therapy will&#xD;
      start after the end of chemotherapy.&#xD;
&#xD;
      All patients with breast conserving therapy or more than 3 axillary lymph node metastases or&#xD;
      in the following cases after mastectomy:&#xD;
&#xD;
        -  T3/T4-carcinoma&#xD;
&#xD;
        -  T2-carcinoma &gt; 3 cm&#xD;
&#xD;
        -  multicentric tumor growth&#xD;
&#xD;
        -  lymphangiosis carcinomatosa or vessel involvement&#xD;
&#xD;
        -  involvement of the pectoralis fascia or a safety margin &lt; 5 mm.&#xD;
&#xD;
      will receive adjuvant radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events related to cancer therapy observed</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Changes in quality of life over time as defined by EORTC QLQ-C30 and QLQ-BR23 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of skeletal/bone-related adverse events observed including osteonecrosis of the jaw</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who develop malignant disease other than recurrence of the breast cancer treated within the trial</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease free survival excluding ipsilateral breast tumor recurrence, regional invasive recurrences, contralateral breast cancer, and all in situ carcinomas</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3754</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>AA-BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AB-BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA-BB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AB-BB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC-DocGemzar adjuvant chemotherapy</intervention_name>
    <arm_group_label>AA-BA</arm_group_label>
    <arm_group_label>AA-BB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC-Doc adjuvant chemotherapy</intervention_name>
    <arm_group_label>AB-BA</arm_group_label>
    <arm_group_label>AB-BB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid i.v. 2 years</intervention_name>
    <arm_group_label>AA-BB</arm_group_label>
    <arm_group_label>AB-BB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid i.v. 5 years</intervention_name>
    <arm_group_label>AA-BA</arm_group_label>
    <arm_group_label>AB-BA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary epithelial invasive carcinoma of the breast pT1-4, pM0&#xD;
&#xD;
          -  Histopathological proof of axillary lymph node metastases (pN1-3) or high risk pN0/NX,&#xD;
             defined as: 'pT ≥ 2 or histopathological grade 3 or age ≤ 35 or negative hormone&#xD;
             receptor status'&#xD;
&#xD;
          -  Complete resection the primary tumor with margins of resection free of invasive&#xD;
             carcinoma not more than 6 weeks ago&#xD;
&#xD;
          -  Females ≥ 18 years of age&#xD;
&#xD;
          -  Performance Status ≤ 2 on Eastern Cooperative Oncology Group (ECOG) Scale&#xD;
&#xD;
          -  Adequate bone marrow reserve: leucocytes ≥ 3.0 x 10^9/l and platelets ≥ 100 x 10^9/l&#xD;
&#xD;
          -  Bilirubin within one fold of the reference laboratory's normal range, aspartate&#xD;
             aminotransferase (ASAT) (serum glutamate oxalacetate transaminase, SGOT), alanine&#xD;
             aminotransferase (ALAT) (serum glutamate pyruvate transaminase, SGPT) and alkaline&#xD;
             phosphatase (AP) within 1,5 fold of the reference laboratory's normal range for&#xD;
             patients&#xD;
&#xD;
          -  Intention of regular follow-up visits for the duration of the study&#xD;
&#xD;
          -  Ability to understand the nature of the study and to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Previous or concomitant cytotoxic or other systemic antineoplastic treatment which is&#xD;
             not part of or allowed within this study&#xD;
&#xD;
          -  History of treatment or disease affecting bone metabolism (e.g., Paget's disease,&#xD;
             primary hyperparathyroidism)&#xD;
&#xD;
          -  Prior treatment with bisphosphonates within the last 6 months&#xD;
&#xD;
          -  Severe renal insufficiency as evidenced by creatinine clearance &lt; 30 ml/min as&#xD;
             calculated using the Cockcroft-Gault formula&#xD;
&#xD;
          -  Second primary malignancy (except in situ carcinoma of the cervix or adequately&#xD;
             treated basal cell carcinoma of the skin)&#xD;
&#xD;
          -  Cardiomyopathy with impaired ventricular function (New York Heart Association&#xD;
             Functional Classification Class (NYHA) &gt; II), cardiac arrythmias influencing left&#xD;
             ventricular ejection fraction (LVEF) and requiring medication, history of myocardial&#xD;
             infarction or angina pectoris within the last 6 months, or arterial hypertension not&#xD;
             being controlled by medication&#xD;
&#xD;
          -  Any known hypersensitivity against docetaxel, epirubicin, cyclophosphamide,&#xD;
             fluorouracil, gemcitabine or any other medication included in the study protocol&#xD;
&#xD;
          -  Use of any investigational agent within 3 weeks prior to inclusion&#xD;
&#xD;
          -  Patients in pregnancy or breast feeding (in premenopausal women anticonception has to&#xD;
             be assured: intra uterine devices, surgical methods of sterilization, or, in hormone&#xD;
             unsensitive tumors only, oral, subcutaneous or transvaginal hormonal, non estrogen&#xD;
             containing contraceptives)&#xD;
&#xD;
          -  Current active dental problems including infection of the teeth or jawbone (maxilla or&#xD;
             mandibular); dental or fixture trauma, or a current or prior diagnosis of&#xD;
             osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after&#xD;
             dental procedures.&#xD;
&#xD;
          -  Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald L Sommer, Prof. Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://success-studie.de/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Harald Leo Sommer</investigator_full_name>
    <investigator_title>Prof. Dr. med. Harald Leo Sommer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

